Bank of America and HC Wainwright raise target prices for Travere Therapeutics' stock.

Bank of America has increased its target price for Travere Therapeutics (NASDAQ: TVTX) from $18 to $19, while HC Wainwright raised theirs from $20 to $23, maintaining a "buy" rating. The stock has a consensus rating of "Moderate Buy" and an average target price of $16.92. Recent earnings showed significant losses, with a return on equity of -269.18%. Insider trading activity included the sale of 30,707 shares worth $352,712 in the last 90 days.